Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
- Conditions
- Progesterone Receptor-Positive Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Breast Adenocarcinoma
- Registration Number
- NCT06401889
- Lead Sponsor
- Mayo Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria:<br><br> - * Female = 18 years<br><br> - Postmenopausal women suitable to receive aromatase inhibitor as per physician's<br> discretion<br><br> - Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen<br> receptor (ER) and/or progesterone receptor (PR) positive per American Society<br> of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline<br> and any human epidermal growth factor receptor 2 (HER2)<br><br> - Patients must not have received any prior chemotherapy or endocrine therapy for<br> their current breast cancer. Patients who received tamoxifen or raloxifene or<br> another agent for prevention of breast cancer may be included<br><br> - Patients willing to avoid any facial procedures including facials, neurotoxin<br> injections, fillers, or lasers during study period<br><br> - Willing and able to provide consent<br><br>Exclusion Criteria:<br><br> - * Patients who have previously taken AIs<br><br> - Patients using prescription tretinoin, neurotoxin injections, fillers, facial<br> lasers, microneedling, or facials within 6 months of study consent
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in skin quality
- Secondary Outcome Measures
Name Time Method